European candidaemia is characterised by notable differential epidemiology and susceptibility pattern; Results from the ECMM Candida III study.

[1]  Eelco F. J. Meijer,et al.  Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. , 2023, The Lancet. Infectious diseases.

[2]  D. Perlin,et al.  Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China , 2022, Emerging microbes & infections.

[3]  F. Dromer,et al.  Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  G. Butler,et al.  Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU , 2022, Emerging microbes & infections.

[5]  F. Paliogianni,et al.  Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy , 2022, Journal of fungi.

[6]  P. Escribano,et al.  Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris. , 2022, The Journal of antimicrobial chemotherapy.

[7]  P. Escribano,et al.  Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the COVID-19 Pandemic , 2022, medRxiv.

[8]  N. Osherov,et al.  Horizontal Gene Transfer of Triazole Resistance in Aspergillus fumigatus , 2022, Microbiology spectrum.

[9]  L. Millon,et al.  Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018) , 2022, mBio.

[10]  J. Guinea,et al.  Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis , 2022, Journal of fungi.

[11]  A. Oliver,et al.  Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  M. Arendrup,et al.  A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints , 2022, Journal of fungi.

[13]  A. Tsakris,et al.  Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey , 2022, Journal of fungi.

[14]  P. Escribano,et al.  Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates , 2021, Antimicrobial agents and chemotherapy.

[15]  L. Pagano,et al.  EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 , 2021, HemaSphere.

[16]  H. Schønheyder,et al.  Update 2016–2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective , 2021, Journal of fungi.

[17]  M. Ilkit,et al.  Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in Turkey: Evolution of a Persisting Challenge , 2021, Frontiers in Cellular and Infection Microbiology.

[18]  M. Arendrup,et al.  ISO standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question! , 2021, The Journal of antimicrobial chemotherapy.

[19]  T. Boekhout,et al.  Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? , 2020, The Journal of antimicrobial chemotherapy.

[20]  M. Arendrup,et al.  How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  P. Hamal,et al.  How to: interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  J. Meis,et al.  Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital , 2020, Frontiers in Cellular and Infection Microbiology.

[23]  A. Kohlenberg,et al.  Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  Brendan R. Jackson,et al.  Burden of Candidemia in the United States, 2017. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  M. Fisher,et al.  Global epidemiology of emerging Candida auris. , 2019, Current opinion in microbiology.

[26]  P. Hamal,et al.  ECMM CandiReg—A ready to use platform for outbreaks and epidemiological studies , 2019, Mycoses.

[27]  P. Mathur,et al.  Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India , 2019, The Journal of antimicrobial chemotherapy.

[28]  B. Kullberg,et al.  Invasive Candidiasis. , 2019, The New England journal of medicine.

[29]  Ronald N. Jones,et al.  Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.

[30]  D. Seidel,et al.  Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together , 2018, Mycoses.

[31]  M. Hendrickx,et al.  Clonal Spread of Candida glabrata Bloodstream Isolates and Fluconazole Resistance Affected by Prolonged Exposure: a 12-Year Single-Center Study in Belgium , 2018, Antimicrobial Agents and Chemotherapy.

[32]  M. Arendrup,et al.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern , 2017, Journal of Clinical Microbiology.

[33]  M. H. Lee,et al.  Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model , 2017, Antimicrobial Agents and Chemotherapy.

[34]  S. Ranque,et al.  Validation of a New Web Application for Identification of Fungi by Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry , 2017, Journal of Clinical Microbiology.

[35]  A. Chowdhary,et al.  Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values , 2017, Antimicrobial Agents and Chemotherapy.

[36]  J. Baddley,et al.  Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). , 2016, The Journal of antimicrobial chemotherapy.

[37]  M. Arendrup,et al.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  M. Arendrup,et al.  Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study , 2015, Antimicrobial Agents and Chemotherapy.

[39]  M. Arendrup,et al.  Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. , 2015, The Journal of antimicrobial chemotherapy.

[40]  K. Kuchler,et al.  Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin Treatment , 2014, Antimicrobial Agents and Chemotherapy.

[41]  J. Rello,et al.  Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain , 2013, Journal of Clinical Microbiology.

[42]  H. Schønheyder,et al.  Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[43]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  M. Arendrup,et al.  Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations , 2012, Antimicrobial Agents and Chemotherapy.

[45]  F. Dromer,et al.  Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients , 2010, Antimicrobial Agents and Chemotherapy.

[46]  S. Katiyar,et al.  A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility , 2008, Antimicrobial Agents and Chemotherapy.

[47]  R. Betts,et al.  Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.

[48]  D. Soll,et al.  Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care Unit , 2005, Journal of Clinical Microbiology.

[49]  J. Vazquez,et al.  Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis , 2005, Antimicrobial Agents and Chemotherapy.

[50]  O. Faure,et al.  Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[51]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[52]  R. Wenzel.  Nosocomial candidemia: risk factors and attributable mortality. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  OUP accepted manuscript , 2022, Journal of Antimicrobial Chemotherapy.

[54]  S. V. van Hal,et al.  Changing epidemiology of candidaemia in Australia. , 2017, The Journal of antimicrobial chemotherapy.

[55]  P. Hamal,et al.  Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[56]  B. Bruun,et al.  Fungemia in a university hospital 1984-1988. Clinical and mycological characteristics. , 1991, Scandinavian journal of infectious diseases.